British Columbia’s life sciences sector is a leader in the development of new products and therapies, particularly in the areas of clinical research and testing, medical devices and biopharmaceuticals.
British Columbia’s life sciences sector enjoys international partnerships that open doors for exports. Organizations from around the world have seen opportunities for discoveries, pharmaceuticals and devices in British Columbia. And there are many more opportunities for new partnerships with key trading partners.
Europe is home to several industry leaders in the life sciences sector, including Merck and GlaxoSmithKline. Europe also has several prominent life sciences clusters. Germany has the largest number of biotech and medtech companies in Europe, while the United Kingdom has the largest pharmaceutical cluster.
Learn more about British Columbia’s export opportunities in Europe.
India is one of the world’s key life sciences markets. Anchored by generic drug manufacturing, the industry has seen significant and increasing investment in research and development since it began recognizing product patents in 2005. The country’s pharmaceutical industry is expected to grow to US$55 billion by 2020. The biotech sector, rooted in research and development, was valued at $11 billion in 2016.
Learn more about British Columbia’s export opportunities in India.
Backed by strong government support, South Korea boasts a robust and growing R&D sector, particularly in biotech. Several innovative drugs have received approval in recent years, providing a dynamic opportunity for British Columbia life science companies.
Learn more about British Columbia’s export opportunities in South Korea.